Description of the management and outcomes of patients with frontline transplant-eligible multiple myeloma in four European countries (France, Germany, Spain and Italy)
- Conditions
- Frontline transplant-eligible multiple myelomaCancerMultiple myeloma
- Registration Number
- ISRCTN88858357
- Lead Sponsor
- Kantar Health (France)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 804
Study population 1 (ongoing FLTE MM population):
1. Being on an ongoing frontline therapy line
2. Being considered either fit for transplant at initial diagnosis, or planned on transplant while on frontline therapy, or having already been transplanted while on frontline therapy
Study population 2 (previous FLTE MM population):
1. Being on an ongoing relapse or refractory multiple myeloma therapy line
2. Having received a previous frontline therapy line
3. Being considered either fit for transplant at initial diagnosis, or having already been transplanted while on frontline therapy
Study population 1 (ongoing FLTE MM population):
1. Receiving the ongoing frontline therapy as part of a randomized controlled trial or early access program
Study population 2 (previous FLTE MM population):
1. Having initiated the frontline induction prior to 2017
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Repartition of the treatments received by the patients with frontline transplant eligible multiple myeloma in induction, consolidation, and maintenance phases and evolution of the repartition by year from 2017 to 2019, extracted from the Cancerology MM database editions of those four countries (French 2020 & 2021, German 2021, Spanish 2020, and Italian 2020 editions) collected for the period from diagnosis to date of data collection.
- Secondary Outcome Measures
Name Time Method